Stay updated with breaking news from Interim Clinical Data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Company to host webcast on Tuesday, March 5, 2024 at 8:30 a.m. ESTInterim clinical data will be presented by Aravindhan Veerapandiyan, M.D., primary investigator of the AFFINITY DUCHENNE trial, at...
51 wet AMD patients with severe disease activity and high treatment burden were randomized to high or low dose 4D-150 or aflibercept control regimen4D-150 was well tolerated with a favorable...
51 wet AMD patients with severe disease activity (mean of 442 µm central subfield thickness & presence of retinal fluid) and high treatment burden...
Initial interim landmark data analysis will be presented by Arshad M. Khanani, M.D., M.A., FASRS, Principal Investigator of the PRISM clinical trial at Angiogenesis, Exudation, and Degeneration 2024...
Published Comprehensive Preclinical Research on SQZ® AAC Platform in Frontiers in ImmunologyContinued Investigational New Drug-Enabling Activities for SQZ® TAC Platform; Submission Expected in First Half of 2023 with Clinical Batches Intended to be Manufactured on the Company’s Point-of-Care SystemAnticipate Interim...